5-[[4-[(6-氯噻吩并[2,3-d]嘧啶-4-基)氨基]-1-哌啶基]甲基]-2-氟苯甲腈 | 866206-54-4

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 5-[[4-[(6-氯噻吩并[2,3-d]嘧啶-4-基)氨基]-1-哌啶基]甲基]-2-氟苯甲腈
• 中文别名: PRX08066;5-[[4-[(6-氯噻吩并[2,3-d]嘧啶-4-基)氨基]-1-哌啶基]甲基]-2-氟苯甲腈
• 英文名称: PRX-08066 free base
• 英文别名: 5-[[4-[(6-chlorothieno[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]-2-fluorobenzonitrile
• CAS: 866206-54-4
• 化学式: C₁₉H₁₇ClFN₅S
• 分子量: 401.9
• InChiKey: IENZFHBNCRQMNP-UHFFFAOYSA-N

物化性质

• 密度：
  1.44
• 溶解度：
  超声波检测下 DMSO 中≥20.1 mg/mL；不溶于水； ≥2.85 mg/mL，乙醇溶液，温和加热

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  93.1
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为产物：
  描述：

  6-chloro-N-(piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine dihydrochloride 、 2-氟-5-甲酰基苯腈 生成 5-[[4-[(6-氯噻吩并[2,3-d]嘧啶-4-基)氨基]-1-哌啶基]甲基]-2-氟苯甲腈
  参考文献：
  名称：

  Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds

  摘要：

  本发明涉及5-HT受体调节剂，尤其是5-HT2B拮抗剂。本发明提供了由式I，II和III表示的新型哌啶基氨基噻吩[2,3-d]嘧啶化合物及其用于治疗包括肺动脉高压、充血性心力衰竭和高血压等疾病的用途。

  公开号：

  US20100113485A1

文献信息

• Piperidinylamino-thieno[2,3-D] pyrimidine compounds
  申请人：Dhanoa S. Dale

  公开号：US20050222176A1

  公开（公告）日：2005-10-06

  The invention relates to 5-HT receptor modulators, particularly 5-HT 2B antagonists. Novel piperidinylamino-thieno [2,3-d] pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.

  这项发明涉及5-HT受体调节剂，特别是5-HT 2B 拮抗剂。公式I、II和III所代表的新型哌啶基氨基噻吩[2,3-d]嘧啶化合物，以及它们用于治疗包括肺动脉高压、充血性心力衰竭和高血压等疾病的用途。
• New piperidinylamino-thieno[2,3-D] pyrimidine compounds
  申请人：Dhanoa S. Dale

  公开号：US20050222175A1

  公开（公告）日：2005-10-06

  The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d]pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism, anxiety, depression, schizophrenia, neural injury and stroke. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also provided.

  该发明涉及5-HT受体拮抗剂。公开了由式I表示的新型哌啶基氨基噻吩[2,3-d]嘧啶化合物，以及其合成和用途，用于治疗由5-HT受体直接或间接介导的疾病。这些疾病包括中枢神经系统疾病，如肺动脉高压、偏头痛、高血压、胃肠道疾病、再狭窄、哮喘、阻塞性气道疾病、前列腺增生和勃起功能障碍、焦虑、抑郁症、精神分裂症、神经损伤和中风。还提供了制备方法、新型中间体和药用盐。
• [EN] DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES<br/>[FR] ACIDES PHÉNOXYPHÉNYL ACÉTIQUES SUBSTITUÉS ENRICHIS EN DEUTÉRIUM ET ACYLSULFONAMIDES
  申请人：DHANOA DALJIT

  公开号：WO2021118826A1

  公开（公告）日：2021-06-17

  The present invention is concerned with deuterium-enriched substituted phenoxy-(3, 4-methylenedioxy)phenylacetic acid and acylsulfonamide derivatives of general structural formula I, their optically active or pure enantiomers and diastereomers, and pharmaceutical salts thereof, Formula (I) These compounds have selective antagonist activity for endothelin receptors or both endothelin and angiotensin II receptors, and are useful in the treatment of diseases mediated by endothelin and angiotensin-II and their receptors.

  本发明涉及富氘代替苯氧基-(3,4-亚甲二氧基)苯乙酸和一般结构式I的酰磺酰胺衍生物，它们的光学活性或纯对映体和非对映异构体，以及它们的药用盐，结构式(I)这些化合物具有对内皮素受体或内皮素和血管紧张素II受体的选择性拮抗活性，并且在治疗由内皮素和血管紧张素II及其受体介导的疾病中有用。
• Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis
  申请人：Gannon Kimberley

  公开号：US20100280050A1

  公开（公告）日：2010-11-04

  The invention provides a method of treating or preventing fibrosis in a subject by administering a 5-HT modulator, e.g., a 5-HT 2B modulator. In particular embodiments, the 5-HT modulator is a piperidinylamino-thieno[2,3-d]pyrimidine compound.

  本发明提供了一种通过给予5-HT调节剂，例如5-HT2B调节剂，来治疗或预防受试者纤维化的方法。在特定实施例中，5-HT调节剂是一种哌啶基氨基噻吩[2,3-d]嘧啶化合物。
• Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds
  申请人：Dhanoa Dale S.

  公开号：US20110082157A1

  公开（公告）日：2011-04-07

  The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d] pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism, anxiety, depression, schizophrenia, neural injury and stroke. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also provided.

  本发明涉及5-HT受体拮抗剂。公开了由式I表示的新型哌啶基氨基噻吩[2,3-d]嘧啶化合物的合成和用途，用于治疗直接或间接由5-HT受体介导的疾病。这些病症包括中枢神经系统疾病，如肺动脉高压、偏头痛、高血压、胃肠道疾病、再狭窄、哮喘、阻塞性气道疾病、前列腺增生和勃起过长、焦虑、抑郁症、精神分裂症、神经损伤和中风。还提供了制备方法、新型中间体和药物盐。